Status:
ACTIVE_NOT_RECRUITING
A Positive Psychology Based Intervention (PATH-C) for Caregivers of HSCT Survivors
Lead Sponsor:
Brigham and Women's Hospital
Collaborating Sponsors:
Dana-Farber Cancer Institute
Robert Wood Johnson Foundation
Conditions:
Hematologic Malignancy
Caregiver
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
The goal of this randomized clinical trial is to evaluate whether a positive psychology intervention (PATH-C) can improve psychological well-being, quality of life, and physical activity in caregivers...
Detailed Description
Family and friend caregivers are vital care providers throughout the entire care continuum for patients with hematologic malignancies undergoing hematopoietic stem cell transplantation (HSCT). These c...
Eligibility Criteria
Inclusion
- Adult caregivers (aged 18 years and older) of patients undergoing allogeneic or autologous HSCT at Dana-Farber Cancer Institute for a hematologic malignancy.
- A relative or a friend who either lives with the patient or has in-person contact with them at least twice per week and is identified as the primary caregiver for HSCT.
- Ability to speak English and able to complete questionnaires with minimal assistance of an interpreter as this is a feasibility trial of the PATH-C intervention which is currently only available in English.
Exclusion
- Caregivers of patients undergoing HSCT for benign hematologic conditions.
- Caregivers with acute or unstable psychiatric conditions which the treating transplant clinician believes prohibits informed consent or compliance with study procedures.
- Cognitive deficits impeding a caregiver's ability to provide informed consent or participate adequately in the study assessed via a commonly used 6-item cognitive assessment with the Brief Interview for Mental Status (BIMS) screening tool that is sensitive and specific for screening for cognitive impairment in research participants.
Key Trial Info
Start Date :
January 1 2024
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
January 31 2027
Estimated Enrollment :
80 Patients enrolled
Trial Details
Trial ID
NCT06153797
Start Date
January 1 2024
End Date
January 31 2027
Last Update
September 18 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Dana Farber Cancer Institute
Boston, Massachusetts, United States, 02215